Table 5.
Correlation of TIGIT expression in ccRCC with clinicopathological characteristics.
| n | PD-1 | Positive rate (%) | P | ||||
|---|---|---|---|---|---|---|---|
| − | + | ++ | +++ | ||||
| Age (year) | 0.367 | ||||||
| ≤50 | 26 | 8 | 10 | 6 | 2 | 69.2 | |
| >50 | 34 | 7 | 15 | 7 | 5 | 79.4 | |
| Sex | 0.757 | ||||||
| Male | 38 | 10 | 10 | 9 | 9 | 73.7 | |
| Female | 22 | 5 | 7 | 6 | 4 | 77.3 | |
| Tumor diameter (cm) | 0.178 | ||||||
| ≤4.0 | 27 | 9 | 4 | 10 | 4 | 66.7 | |
| >4.0 | 33 | 6 | 12 | 8 | 7 | 81.8 | |
| Fuhrman grade | 0.551 | ||||||
| Well differentiated | 45 | 13 | 17 | 10 | 5 | 71.1 | |
| Intermediately differentiated | 10 | 1 | 1 | 5 | 3 | 90.0 | |
| Poorly differentiated | 5 | 1 | 1 | 1 | 2 | 80.0 | |
| TNM stage | 0.341 | ||||||
| Stage I | 40 | 12 | 11 | 13 | 4 | 70.0 | |
| Stage II | 16 | 3 | 3 | 4 | 6 | 81.3 | |
| Stage III | 4 | 0 | 1 | 1 | 2 | 100.0 | |
Chi-square test with continuity correction: P<0.05.